Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AURA Aura Biosciences	$7.23 +4.2%	$6.60	$4.34 ▼ $12.38	$348.86M	0.46	164,658 shs	212,921 shs
BYSI BeyondSpring	$2.00 -0.5%	$2.30	$0.98 ▼ $3.44	$81.05M	0.26	26,759 shs	53,850 shs
ESPR Esperion Therapeutics	$1.94 +8.4%	$1.29	$0.69 ▼ $3.94	$354.78M	0.82	6.06 million shs	9.26 million shs
NBTX Nanobiotix	$7.96 +7.6%	$5.56	$2.76 ▼ $8.47	$354.78M	0.45	7,653 shs	47,564 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AURA Aura Biosciences	+4.18%	+5.70%	+7.11%	+39.58%	-11.29%
BYSI BeyondSpring	-0.50%	-2.44%	-12.66%	+19.05%	+8.70%
ESPR Esperion Therapeutics	+8.38%	+1.04%	+64.41%	+149.61%	+7.78%
NBTX Nanobiotix	+6.44%	+16.09%	+54.64%	+117.00%	+65.57%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AURA Aura Biosciences	2.1335 of 5 stars	3.6	0.0	0.0	0.0	2.7	3.3	0.0
BYSI BeyondSpring	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ESPR Esperion Therapeutics	4.269 of 5 stars	3.4	3.0	0.0	3.9	3.3	1.7	0.6
NBTX Nanobiotix	0.6545 of 5 stars	1.3	3.0	0.0	0.0	2.7	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AURA Aura Biosciences	3.25	Buy	$22.00	204.29% Upside
BYSI BeyondSpring	0.00	N/A	N/A	N/A
ESPR Esperion Therapeutics	2.80	Moderate Buy	$7.00	260.82% Upside
NBTX Nanobiotix	2.50	Moderate Buy	$8.00	0.45% Upside

Current Analyst Ratings Breakdown

Latest BYSI, AURA, NBTX, and ESPR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	AURA Aura Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00
6/17/2025	ESPR Esperion Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
5/28/2025	AURA Aura Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$22.00
5/23/2025	AURA Aura Biosciences	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$19.00

(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AURA Aura Biosciences	N/A	N/A	N/A	N/A	$3.04 per share	N/A
BYSI BeyondSpring	$1.75M	46.08	N/A	N/A	($0.37) per share	-5.41
ESPR Esperion Therapeutics	$332.31M	1.16	$0.03 per share	74.50	($1.97) per share	-0.98
NBTX Nanobiotix	-$11.61M	-32.89	N/A	N/A	($1.51) per share	-5.27

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AURA Aura Biosciences	-$86.92M	-$1.90	N/A	N/A	N/A	N/A	-58.63%	-49.74%	8/13/2025 (Estimated)
BYSI BeyondSpring	-$11.12M	N/A	0.00	∞	N/A	N/A	N/A	N/A	8/14/2025 (Estimated)
ESPR Esperion Therapeutics	-$51.74M	-$0.49	N/A	N/A	N/A	-35.84%	-0.91%	-28.84%	N/A
NBTX Nanobiotix	-$73.73M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	9/17/2025 (Estimated)

Latest BYSI, AURA, NBTX, and ESPR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	AURA Aura Biosciences	-$0.49	-$0.47	+$0.02	-$0.47	N/A	N/A
8/13/2025	Q2 2025	BYSI BeyondSpring	N/A	-$0.04	N/A	-$0.04	N/A	N/A
8/5/2025	Q2 2025	ESPR Esperion Therapeutics	-$0.17	-$0.02	+$0.15	-$0.02	$62.55 million	$82.39 million
5/15/2025	Q1 2025	AURA Aura Biosciences	-$0.47	-$0.55	-$0.08	-$0.55	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AURA Aura Biosciences	N/A	N/A	N/A	N/A	N/A
BYSI BeyondSpring	N/A	N/A	N/A	N/A	N/A
ESPR Esperion Therapeutics	N/A	N/A	N/A	N/A	N/A
NBTX Nanobiotix	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AURA Aura Biosciences	N/A	11.06	11.06
BYSI BeyondSpring	N/A	2.49	2.49
ESPR Esperion Therapeutics	N/A	1.18	0.81
NBTX Nanobiotix	N/A	1.04	1.04

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AURA Aura Biosciences	96.75%
BYSI BeyondSpring	40.29%
ESPR Esperion Therapeutics	47.39%
NBTX Nanobiotix	38.81%

Insider Ownership

Company	Insider Ownership
AURA Aura Biosciences	6.30%
BYSI BeyondSpring	29.31%
ESPR Esperion Therapeutics	1.70%
NBTX Nanobiotix	3.45%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AURA Aura Biosciences	50	50.27 million	47.10 million	Not Optionable
BYSI BeyondSpring	80	40.32 million	28.50 million	Optionable
ESPR Esperion Therapeutics	200	198.20 million	194.83 million	Optionable
NBTX Nanobiotix	100	47.94 million	46.29 million	Not Optionable

BYSI, AURA, NBTX, and ESPR Headlines

Recent News About These Companies

Nanobiotix (NASDAQ:NBTX) Stock Price Up 2.9% - Should You Buy?

July 30, 2025 | marketbeat.com

Guggenheim Reaffirms Their Buy Rating on Nanobiotix (NBTX)

July 25, 2025 | theglobeandmail.com

NANOBIOTIX Announces Regulatory Harmonization and New Composition of Matter Patent Filed for JNJ-1900 (NBTXR3) - Morningstar

July 8, 2025 | morningstar.comM

NANOBIOTIX Announces Regulatory Harmonization and New Composition of Matter Patent Filed for JNJ-1900 (NBTXR3)

July 7, 2025 | globenewswire.com

NANOBIOTIX to Participate in the Jefferies Global Healthcare Investor Conference

May 28, 2025 | globenewswire.com

Nanobiotix Provides First Quarter 2025 Operational and Financial Update

May 21, 2025 | globenewswire.com

Nanobiotix to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ

May 12, 2025 | globenewswire.com

Nanobiotix Reveals Favorable Results Of JNJ-1900 Study Pancreatic Cancer; Seeks Further Evaluation

May 5, 2025 | finanznachrichten.de

Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer

May 5, 2025 | globenewswire.com

Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call

April 30, 2025 | globenewswire.com

Nanobiotix price target lowered to $8 from $12 at Guggenheim

April 5, 2025 | markets.businessinsider.com

Nanobiotix (NBTX) Gets a Hold from UBS

April 5, 2025 | markets.businessinsider.com

Nanobiotix S.A. (NBTX) Q4 2024 Earnings Call Transcript

April 3, 2025 | seekingalpha.com

NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results

April 2, 2025 | globenewswire.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Pfizer (PFE), Nanobiotix (NBTX) and PTC Therapeutics (PTCT)

April 2, 2025 | theglobeandmail.com

NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025

March 31, 2025 | globenewswire.com

Nanobiotix reports promising NSCLC treatment study results

March 29, 2025 | investing.com

Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC

March 27, 2025 | globenewswire.com

NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3)

March 21, 2025 | djournal.comD

NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference

March 20, 2025 | globenewswire.com

Nanobiotix amends global licensing agreement with Janssen Pharmaceutica

March 18, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

BYSI, AURA, NBTX, and ESPR Company Descriptions

Aura Biosciences NASDAQ:AURA

$7.23 +0.29 (+4.18%)

Closing price 08/13/2025 04:00 PM Eastern

Extended Trading

$7.21 -0.02 (-0.28%)

As of 08/13/2025 06:04 PM Eastern

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

BeyondSpring NASDAQ:BYSI

$2.00 -0.01 (-0.50%)

Closing price 08/13/2025 04:00 PM Eastern

Extended Trading

$2.00 +0.00 (+0.25%)

As of 08/13/2025 04:12 PM Eastern

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.

Esperion Therapeutics NASDAQ:ESPR

$1.94 +0.15 (+8.38%)

Closing price 08/13/2025 04:00 PM Eastern

Extended Trading

$1.94 0.00 (0.00%)

As of 08/13/2025 07:56 PM Eastern

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Nanobiotix NASDAQ:NBTX

$7.96 +0.56 (+7.62%)

Closing price 08/13/2025 03:58 PM Eastern

Extended Trading

$7.98 +0.02 (+0.20%)

As of 08/13/2025 07:58 PM Eastern

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time